BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact

denovoMATRIX Launches New Enabling Technology for High-Quality Induced Pluripotent Stem Cell Culture

March 22, 2021 By Cade Hildreth (CEO) Leave a Comment

denovoMARTIX ipsc culture

DRESDEN, Germany, Mar. 22, 2021 (BioInformant) — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced the launch of a new range of products for the expansion, banking and maintenance of induced pluripotent stem cells (iPSC). The product line, termed myMATRIX iPSC, are chemically defined, ready-to-use consumables, designed to simplify and accelerate iPSC culture.  [Read more…]

5 / 5 ( 12 votes )

Filed Under: iPS Cells, Press Releases

USPTO Issues New Patents for Cell Source’s Veto Cell Technology

March 19, 2021 By Cade Hildreth (CEO) Leave a Comment

CellSource
Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections

March 19, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the Company”), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ transplants. In addition, Veto Cells can durably treat malignant and non-malignant blood diseases through active immune response management. Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. [Read more…]

5 / 5 ( 3 votes )

Filed Under: CAR-T, Cell Therapy, Press Releases

Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

March 18, 2021 By Cade Hildreth (CEO) Leave a Comment

celularity-fast-track-designation

FLORHAM PARK, N.J., March 18, 2021 — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM. [Read more…]

5 / 5 ( 2 votes )

Filed Under: Cell Therapy, Press Releases

Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients

March 17, 2021 By Cade Hildreth (CEO) Leave a Comment

Organicell Zofin

Organicell Regenerative Medicine (OTCBB: BPSR), a clinical-stage biopharma company developing exosome-based regenerative therapies, has announced the release of a Case Report in the peer reviewed journal Frontiers in Medicine. This case study highlights the therapeutic potential of Organicell’s proprietary therapeutic, Zofin™, and its continued success as a drug candidate. [Read more…]

5 / 5 ( 1 vote )

Filed Under: Cell Therapy, Exosomes

Celonic to Expand Cell and Gene Therapy CDMO Business with Facility in Switzerland

March 16, 2021 By Cade Hildreth (CEO) Leave a Comment

Celonic Cell and Gene Therapy CDMO
Celonic to Boost Its Cell and Gene Therapy (CGT) Production with a Facility in the Upcoming Life Science Parket Rheintal, located in Stein, Switzerland.

Celonic Group, a leading global CDMO specializing in the development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office space. The facility will span 91,500 square feet (8,500 sqm) in the WST-222 building at the Novartis-operated Life Science Park Rheintal. [Read more…]

5 / 5 ( 5 votes )

Filed Under: Cell Therapy, Press Releases

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 250
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Vitro Biopharma

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

MSC market

How the MSC Market is Coming of Age in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.